ScholarWorks@Korea University: Lee, Young Ho

Detailed Information

Lee, Young Ho (이영호)

Graduate School (Department of Biomedical Sciences)

Research Area

Tel 안5645
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Metaanalysis:117||Polymorphism:104||Rheumatoid arthritis:67||metaanalysis:56||polymorphism:50||rheumatoid arthritis:32||Systemic lupus erythematosus:22||systemic lupus erythematosus:20||Autoimmune diseases:20||network metaanalysis:19||Network metaanalysis:15||Mendelian randomization:13||Pathwaybased analysis:12||Genomewide association study:12||Osteoarthritis:10||SLE:9||Ankylosing spondylitis:8||Efficacy:8||Vitamin D receptor:7||lupus nephritis:6||Alzheimer's disease:6||Angiotensinconverting enzyme:6||Protein tyrosine phosphatase nonreceptor 22:6||Safety:6||Psoriasis:6||treatment:6||Behcet's disease:6||TNFalpha:5||Cytotoxic T lymphocyte antigen4:5||Gout:5||disease activity:5||Asthma:5||Vasculitis:5||RA:5||Level:5||Lupus nephritis:5||Fibromyalgia:5||Interleukin10:5||gout:5||efficacy:5||Inflammation:4||Tolllike receptor:4||Tacrolimus:4||pathwaybased analysis:4||Parkinson's disease:4||Systemic sclerosis:4||MicroRNA:4||IL6:4||CYC:4||Susceptibility:4||activity:4||Microarray:4||&nbsp:4||Activity:4||tofacitinib:4||psoriatic arthritis:3||FAS:3||biologics:3||Tumor necrosis factor:3||protein tyrosine phosphatase nonreceptor 22:3||Gene expression:3||Ethnicity:3||RHEUMATOID ARTHRITIS:3||CTLA4:3||Periodontitis:3||Bone mineral density:3||Interleukin1:3||psoriasis:3||COMT:3||VEGF:3||secukinumab:3||Coffee:3||Vitamin D:3||Tofacitinib:3||safety:3||epidemiology:3||Endothelial nitric oxide synthase:3||vasculitis:3||MTHFR:3||CCR5Delta 32 polymorphism:3||cardiovascular disease:3||Diagnostic accuracy:3||systemic sclerosis:3||genomewide association study:3||Polymorphisms:3||Macrophages:3||JAK inhibitors:3||Interleukin18:3||methotrexate:3||MMF:3||hepatitis B virus reactivation:2||FCRL3:2||ADAM33:2||POPULATION:2||Review:2||rituximab:2||SLC2A9:2||Leptin:2||TNF blockers:2||HLAG:2||Remission:2||tacrolimus:2||Mendelian randomization analysis:2||Association:2||level:2||mendelian randomization:2||Mortality:2||SUSCEPTIBILITY LOCI:2||RHEUMATOIDARTHRITIS:2||RISK:2||Multiple sclerosis:2||MICA:2||PPAR gamma:2||Pulmonary tuberculosis:2||multiple sclerosis:2||Synovial macrophages:2||PON1:2||Baricitinib:2||Smoking:2||Methotrexate:2||Placebo effect:2||RPL:2||GSTM1:2||Amyotrophic lateral sclerosis:2||Interleukin23R:2||AUTOIMMUNEDISEASES:2||Bioinformatics:2||variant:2||Secukinumab:2||ADHD:2||Gene:2||Gene frequency:2||vitamin D receptor:2||Juvenile idiopathic arthritis:2||Psoriatic arthritis:2||Alcohol intake:2||CD40:2||Janus kinase inhibitors:2||IRF5:2||PTPN22:2||Prolactin:2||Polymorphism, genetic:2||MEDLINE:2||ITGAM:2||osteoarthritis:2||TNF inhibitors:2||IL17:2||biosimilar:2||Genetic association studies:2||vitamin D:2||IFN:2||Type 1 diabetes:2||rheumatic diseases:2||diagnostic accuracy:2||vitiligo:2||CD226:2||SYSTEMICLUPUSERYTHEMATOSUS:2||ankylosing spondylitis:2||genetic:2||BMD:2||Causal association:2||smoking:2||responsiveness:2||spondyloarthropathy:2||ICAM1:2||Autoimmune disease:2||p53:2||autoimmune diseases:2||FCGR polymorphism:2||ERAP1:2||MCP1:2||tacrolimus plus MMF:1||Relative efficacy:1||Anfalligkeit:1||Serine proteinase inhibitors:1||Genetic predisposition to disease:1||Pulmonary fibrosis:1||Abstract:1||MPV:1||Tolerability:1||triple therapy:1||visfatin:1||Advantage:1||Deficiency:1||Scleroderma:1||Takayasu arteritis:1||MHC2TA:1||NFKB1:1||FCGR3B:1||Copy number variation:1||FOXP3:1||Association study:1||Paraoxonase:1||MTX toxicity:1||Nonresponsiveness:1||Response:1||tuberculin skin tests:1||Vitiligo:1||Prostaglandin D2 receptor:1||EVEROLIMUS:1||SYSTEM:1||ETIOLOGY:1||LATVIAN PATIENTS:1||VARIANT:1||Phox homology domain containing serine/threonine kinase:1||Omega3 polyunsaturated fatty acids:1||Mannosebinding lectin:1||cyclophosphamide:1||1:1||25(OH)2D3:1||genetic polymorphism:1||INTERLEUKIN 1:1||GENETIC POLYMORPHISM:1||corticosteroid:1||AntiCCP:1||COVID19 vaccine:1||JAK inhibitor:1||Nocebo effect:1||ANCA vasculitis&nbsp:1||allopurinol:1||juvenile idiopathic arthritis:1||Biological agent:1||DISH:1||Interstitial lung disease:1||Osteopontin:1||Unterernahrung:1||Mycophenolate mofetil:1||tolerability:1||dmards (synthetic):1||abatacept:1||filgotinib:1||Bone erosion:1||uric acid level:1||Cyclophosphamide:1||Type 2 diabetes:1||Bone density:1||Metaanalyse:1||AntiP. gingivalis antibody:1||IL6, biologics:1||infliximab:1||US:1||Etiology:1||Biological markers:1||Leflunomide:1||Adipokines:1||connective tissue disease:1||DECT:1||Drug side effects:1||Biomarkers:1||CYP2D6:1||MIF:1||Imaging:1||Etoricoxib:1||Celecoxib:1||Naproxen:1||mortality:1||Linkage disequilibrium:1||HLAB51 antigen:1||sarcoidosis:1||Ethnic groups:1||Inflammatory disease:1||Polymorphism, single nucleotide:1||Vascular endothelial growth factor:1||Tea:1||Disease susceptibility:1||Mannosebinding lectin gene:1||Promoter regions, genetic:1||Breast cancer:1||antiCCP antibodies:1||cytotoxic T lymphocyte antigen4:1||antitumor necrosis factor therapy:1||Monocytes:1||Interferon regulatory factor 5:1||hepatitis B virus occult carrier:1||Guideline:1||RAPAMYCIN:1||HUMAN OX40 LIGAND:1||SUPERFAMILY:1||COMPLEMENT:1||MOLECULAR NETWORKS:1||NEPHRITIS:1||TOOL:1||Rituximab:1||IL1 beta:1||STAT4:1||Chondroitin:1||Knee:1||AAV:1||leptin:1||Clinical efficacy:1||toxicity:1||Olokizumab:1||Neutrophiltolymphocyte ratio:1||Platelettolymphocyte ratio:1||Thrombosis:1||IL37 protein:1||Anticyclic citrullinated peptide antibody:1||Matrix metalloproteinases:1||xanthine oxidase inhibitor:1||Alzheimer ' s disease:1||Scleroderma, diffuse:1||NLR:1||Biosimilar:1||Osteonecrosis:1||BLK:1||Correlation:1||ATIC:1||Side effects:1||Histocompatibility antigens class I:1||FCG receptor:1||Peripheral tolerance:1||procalcitonin:1||melanoma:1||Estrogen receptor:1||Complement system proteins:1||ultrasonography:1||PAL1:1||Sarcoidosis:1||cervical cancer:1||DMARD:1||Schizophrenia:1||tolllike receptor:1||IL18:1||ovarian cancer:1||MAMMALIAN TARGET:1||ANALOGS:1||GENOMEWIDE ASSOCIATION:1||IDENTIFICATION:1||GENE POLYMORPHISMS:1||GENE:1||Migration inhibitory factor:1||interleukin6:1||erythematosus:1||Lupus:1||TUMOR NECROSIS FACTORalpha INHIBITORS:1||SHARED EPITOPE:1||Fc receptors:1||bone mineral density:1||RF:1||biological agents:1||Gut microbiome:1||immunosuppressants:1||mavrilimumab:1||topiroxostat:1||bone density:1||osteoporosis:1||interleukin 17:1||leptin receptor:1||Blood cell count:1||Lupus erythematosus:1||Casecontrol studies:1||Upadacitinib:1||Interleukin17:1||YKL40:1||upadacitinib:1||NIH regimen:1||Genetic polymorphism:1||RZA:1||Telomere length:1||knee osteoarthritis:1||5HTTLPR:1||Sarilumab:1||Adalimumab:1||adiponectin:1||MIF level:1||Bayesian network metaanalysis:1||AntiRA33 antibody:1||Venous thromboembolism:1||NLRP3:1||Interleukin 1:1||type 1 diabetes:1||IFNgamma:1||schizophrenia:1||MUC5B:1||abdominal aortic aneurysm:1||susceptibility:1||CD24:1||ulcerative colitis:1||TNFalpha polymorphism:1||breast cancer:1||interleukin1:1||Major depressive disorder:1||MMP:1||TLR:1||antitumour necrosis factor therapy:1||preeclampsia:1||Interleukin23 R:1||Rheumatic diseases:1||SURVIVAL:1||Genomewide association studies:1||TCELLS:1||GENES:1||LOCI:1||GLU298ASP:1||REGION:1||RESPONSES:1||TNF:1||polymorphisms:1||METAANALYSIS:1||non&#8208:1||steroidsparing effect:1||idiopathic arthritis:1||nocebo:1||biosimilars:1||network&nbsp:1||arthritis:1||fracture:1||Acute gout:1||MTX efficacy:1||Azathioprine:1||Diffuse:1||Mean platelet volume:1||relationship:1||giant cell arteritis:1||Filgotinib:1||Frequency:1||BMI:1||Cohort studies:1||MiR146a:1||rheumatoid arthritis:1||Statistical analysis:1||Risk factors:1||HLA antigens:1||Belimumab:1||Prolactin level:1||Osteoporosis:1||pulmonary hypertension:1||Polymyositis:1||BANK1:1||Specificity:1||deficiency:1||Duloxetine:1||Pregabalin:1||Hormone receptors, nuclear:1||PADI4:1||pancreatic cancer:1||Apoptosis:1||Glaucoma:1||Pathway analysis:1||Mucocutaneous lymph node syndrome:1||FCGR3A:1||Variant alleles:1||Attentiondeficit/hyperactivity disorder:1||shared epitope:1||TRAF1C5:1||FCGR:1||NITRICOXIDE SYNTHASE:1||AUTOIMMUNE:1||DISEASES:1||Tyrosine kinase 2:1||JAPANESE POPULATION:1||Interleukin6:1||beta(2)glycoprotein I:1||Pregnancy:1||mycophenolate mofetil:1||TUMOR NECROSIS FACTORalpha POLYMORPHISM:1||Glucosamine:1||Structural efficacy:1||systemic juvenile:1||canakinumab:1||ankylosing spondilitis:1||health services research:1||ankylosing:1||ixekizumab:1||psoriatic:1||Low disease activity:1||Nintedanib:1||baricitinib:1||tanezumab:1||Causality:1||tocilizumab:1||human:1||Polymorphismus:1||Uric acid:1||educational attainment:1||Interleukin23 receptor:1||Korea:1||PLR:1||Limitation:1||survival:1||Evidencebased medicine:1||Monocyte chemoattractant protein1:1||Confidence Interval:1||Telomere:1||length:1||Diseasemodifying, antirheumatic drugs:1||PTPRC:1||Responsiveness:1||Diabetic nephropathy:1||Behcet syndrome:1||Genotype:1||IPF:1||Crohn's disease:1||Autoimmunity:1||sialography:1||Biologic agent:1||PCOS:1||Systematic review:1||Sweet’s syndrome:1||Treatment:1||Candidate gene:1||GSTP1:1||SNPS:1||Metaanalysis:1||Antiphospholipid syndrome:1||Systemic lupus:1||systematic review:1||network meta&#8208:1||guselkumab:1||polymyalgia rheumatica:1||Neuroblastoma:1||maintenance therapy&nbsp:1||.:1||autoimmunity:1||spondylitis:1||voclosporin:1||multitarget therapy:1||malnutrition:1||inflammation:1||Osteoarthrose:1||Polyarthritis:1||adult onset still's disease:1||DMARDs (synthetic):1||lesinurad:1||TYMS polymorphism:1||Ustekinumab:1||Immunosuppressive agents:1||Dermatomyositis:1||Immune system:1||MS:1||GSTT1:1||Cancer:1||CCR5:1||GSTs:1||HLAB27 antigen:1||CRP:1||MicroRNAs:1||Apolipoprotein E:1||glioma:1||TNFR:1||Biologics:1||GWAS:1||monocyte chemoattractant protein1:1||ENVIRONMENT:1||ARTERY:1||TRANSCRIPTION FACTORS:1||HETEROGENEITY:1||GOUT:1||CYP24:1||LRP5:1||PDCD1:1||POLYMORPHISM:1||analysis:1||TNF biologics:1||RCT:1||dotinurad &nbsp:1||benzbromarone network metaanalysis:1||Arthritis:1||Tolllike receptor 9:1||Tolllike receptor 7:1||Growth hormone:1||Ghrelin:1||systemic:1||Euroregimen:1||Cardiomyopathy:1||Publication:1||Rheumatology:1||GCA:1||Mortalitat:1||Apremilast:1||Anticitrullinated protein antibodies:1||BDNF:1||TNFI:1||AZA:1||AntiSa antibody:1||Connective tissue diseases:1||Urinalysis:1||TGFbeta 1:1||Calprotectin:1||Giant cell arteritis:1||Sensitivity:1||TYK2:1||Milnacipran:1||Literature review:1||Major histocompatibility complex:1||bacterial infection:1||TNFalpha inhibitors:1||Preeclampsia:1||Genetic polymorphisms:1||Publication bias:1||IL6 polymorphisms:1||Sjogren's syndrome:1||Asporin:1||brainderived neurotrophic factor:1||LTalpha:1||BD:1||T1D:1||Endometriosis:1||angiotensinconverting enzyme:1||TREM1:1||1,25Dihydroxyviamin D3:1||interferongamma release assays:1||interleukin4:1||interleukin12B:1||OSTEOCLASTS:1||CELLS:1||EXPRESSION:1||RECEPTORS:1||FAMILIES:1||A20:1||Tumor necrosis factor alpha inducible protein 3:1||Associated vasculitis:1||1,25Dihydroxyvitamin D3:1||RESPONSIVENESS:1||Osteoprotegerin:1||FC gamma RECEPTOR:1||adjusted indirect comparison:1||etanercept:1||gout &nbsp:1||febuxostat &nbsp:1||vitamin d receptor:1||asthma:1||ankylosis:1||IL33:1||Uratelowering therapy:1||Autoimmunkrankheiten:1||systemische Sklerose:1||Calcineurin:1||Limited:1||Tolllike receptor 4:1||

RSS_1.0 RSS_2.0 ATOM_1.0

145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE